Clinical Research Study Finder

Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!

Find a Clinical Research Study

1 - 10 of 211

Metabolic MRI: Pilot Testing

The purpose of this research study is to test and adapt new techniques for performing magnetic resonance imaging (MRI). MRI provides pictures of the inside of the body and information about chemicals the body makes. Here are some examples of what we hope to accomplish:

1. Adapt MRI techniques used at other institutions for use on CHOP MRI scanners

2. Increase the amount of information learned from each MRI image

The research sequences involve changing the settings of the magnetic resonance scanner. By research sequences we mean that they are not approved by the US Food and Drug Administration (FDA) for clinical use. The data we obtain will help the FDA evaluate whether or not they can eventually approve the sequences for clinical use.

We are seeking to enroll healthy volunteers, 18 years of age and above. Pregnant females excluded for safety purposes.

Study of Efficacy and Safety of Tisagenlecleucel in Children and Young Adults with HR B-ALL that is end-consolidation MRD Positive (AALL1721/CASSIOPEIA)

The purpose of this study is to test if the CD19 CAR T cell product tisagenlecleucel (also referred to as CTL019, or Kymriah™) is safe and has beneficial effects in children and young adults who have newly diagnosed high-risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL) that remains MRD-positive after 2 cycles of chemotherapy. The study is enrolling children and young adults between the ages of 1-25 who have received induction and consolidation chemotherapy for HR B-ALL but were still found to have remaining disease (MRD). If you agree to join in this study, you will get one dose of the tisagenlecleucel cells administered by intravenous infusion and be followed for leukemia response. This study also involves blood draws and assessments. Reimbursement for travel may be provided. If you have questions or would like to learn more about the study, please contact the Cancer Immunotherapy Program at (215) 425-7193. The Principal Investigator is Dr. Shannon Maude and the Immunotherapy Nurse Navigator is Brooke Leibfreid, RN.


 The purpose of this study is to investigate the safety and effectiveness of eltrombopag in treating children and adolescents with newly diagnosed immune thrombocytopenia (ITP). Patients aged between 1 to <18 years with newly diagnosed ITP will be eligible to enroll if they consent to participate within ten days from diagnosis and have not received any prior therapy or if they have failed standard management and are within the first three months from diagnosis. If you choose to participate, you will be on study for about 1 year. You will be randomly assigned to receive the study drug eltrombopag or standard therapy. Participation in this study includes weekly procedures such as assessments, physical exams, review of medical records, blood draws and questionnaires for 12 weeks and then about monthly or less often for up to 1 year. 

Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism (for children under 1 year of age)

This study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 7 days and 12 months who have congenital hyperinsulinism. Dasiglucagon will be given as a subcutaneous infusion while patients are admitted to the hospital. Other treatments for hyperinsulinism may be changed as allowed while maintaining safe blood sugar levels. For the second part of the study, patients may be able to go home on the medication.

Online Mindfulness Course for Pediatric IBD

Inflammatory Bowel Disease (IBD) can sometimes add stress to your life and that may affect your physical symptoms of pain and stool habits. In this study, we want to know if practicing mindfulness via an online Mindfulness-based stress reduction (MBSR) course taught by a trained teacher can help with your IBD. If you are a patient with IBD, who is between 12-19 years of age, you might be eligible to participate in an 8 week long MBSR group course online. You will answer a series of questionnaires and submit stool samples 3 times over the course of the study, and you will also participate in 1 focus group to discuss your experience in the study. You will be compensated for your participation.

Ribociclib With Everolimus And Dexamethasone For Relapsed ALL

CHOP, in collaboration with Dana-Farber Cancer Institute, is conducting a study for children, adolescents, and young adults up to 31 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drugs ribociclib and everolimus to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email

RGX-111 Gene Therapy in Patients With Mucopolysaccharidosis Type I (MPS I)

This study will evaluate the safety and tolerability of RGX-111 in patients with Mucopolysaccharidosis Type I with a neurocognitive deficit that are at least 4 months old. This study involves administration of the RGX-111, general anesthesia, lumbar puncture, blood draws, MRI, ultrasound, electrocardiogram, echocardiogram, hearing test, and chart review. If you have questions or would like to learn more about the study, please contact the Principal Investigator, Dr. Ficicioglu at (215) 590-3376. 

Phenotyping Congenital Hyperinsulinism

The Congenital Hyperinsulinism Center at the Children’s Hospital of Philadelphia is working on a research study to better understand how people with hyperinsulinism may have different blood sugar responses to certain tests (like fasting or drinking a high-protein shake) when compared to people without hyperinsulinism. This study will involve a screening visit where we will ask you about your medical history and any known episodes of low blood sugar. Depending on your responses during the interview, you will be asked to complete up to five tests at our outpatient research center. These tests include fasting, drinking a high-protein shake, drinking a high-sugar drink, eating a regular meal, and exercising on a stationary bike. We will collect blood samples from an IV throughout the tests to measure certain blood levels like glucose and insulin. You will be compensated for some or all of your travel costs and you will receive payment for your time. If you are interested in learning more, please contact us at

Sleep and Growth Study 2

The Children’s Hospital of Philadelphia is seeking healthy adolescents between the ages of 12-13, who are currently in the 7th grade, to participate in the Sleep and Growth Study 2. The purpose of this research is to learn more about the changes in sleep and body size in adolescents as they transition from middle to high school. Participants will be asked to visit CHOP so that we can measure their bone density. Following this visit, participants will wear a sleep tracker over a 2-week period and speak to a team member by phone on three occasions about the types of food eaten in the previous 24 hours. If you and your child agree to participate, the study will involve 3 visits over approximately 2 years. All participants are compensated for their time and effort. For more information and study details, please call 215-590-2383, ext. 1, or email

MRI Study for Prediction of ASD

This study seeks to understand the key differences and similarities in brain development between infants whose siblings do and do not have autism. Participants will be asked to make 3 visits to CHOP over time to complete cognitive and behavioral testing and a non-invasive MRI. Participants will be compensated for their time and receive a written feedback report.